[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100530033":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":27,"centralContacts":28,"locations":34,"responsibleParty":51,"collaborators":54,"id":57,"slug":58,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":27,"eligibilityCriteria":63,"healthyVolunteers":59,"sex":64,"minAge":65,"maxAge":66,"enrollmentInfo":67,"targetDuration":27,"studyType":70,"phases":71,"briefSummary":73,"conditions":74,"keywords":77,"overallStatus":37,"whyStopped":27,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},{"fullName":5,"class":6},"University of Nicosia","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Probiotics","EXPERIMENTAL","Participants received 1 capsule daily of probiotics, administered orally for 16 weeks.",[13],"Drug: Probiotic Blend Capsule",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Participants received 1 capsule daily of placebo, administered orally for 16 weeks.",[13],[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Probiotic Blend Capsule","20 million CFU (Lactobacillus paracasei, Lactobacillus plantarum, Lactobacillus rhamnosus, Lactobacillus helveticus, Bifidobacterium breve)",[15,9],[26],"Ultrabiotique Equilibre 30 Vitavea",null,[29],{"name":30,"role":31,"phone":32,"phoneExt":27,"email":33},"Nicoletta Nicolaou","CONTACT","+35722471903","nicolaou.nic@unic.ac.cy",[35],{"facility":36,"status":37,"city":38,"state":27,"zip":27,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"The Cyprus Institute of Neurology and Genetics","RECRUITING","Nicosia","Cyprus","CY",{"type":42,"coordinates":43},"Point",[44,45],33.35397,35.17284,{"lat":45,"lon":44},[48],{"name":49,"role":31,"phone":27,"phoneExt":27,"email":50},"Ioanna Kousiappa","ioannak@cing.ac.cy",{"type":52,"investigatorFullName":30,"investigatorTitle":53,"investigatorAffiliation":5,"oldNameTitle":27,"oldOrganization":27},"PRINCIPAL_INVESTIGATOR","Associate Professor",[55],{"name":56,"class":6},"Cyprus Institute of Neurology and Genetics","100530033","early-phase-1-probiotics-in-mild-alzheimers-disease-100530033",false,"NCT06181513","Probiotics in Mild Alzheimer's Disease","Effect of Probiotics on Cognitive Functioning of Patients With Mild Alzheimer's Disease","Inclusion Criteria:\n\n* Adults ≥65 years, able to give consent\n* Mini-Mental State Examination (MMSE) scores 19-23 (mild AD)\n* approximately equal male:female ratio\n\nExclusion Criteria:\n\n* Inability to give consent\n* other neurological disease\n* relevant psychiatric disorders (e.g. major depression)\n* gastrointestinal\u002Fmetabolic conditions\n* history of alcohol\u002Fsubstance dependence\n* use of systemic antibiotics in the previous 6 months\n* corticosteroid use\n* immune stimulating medications\n* immunosuppressive agents\n* probiotics consumption in the previous 6 months.\n* immunosuppression\n* structural heart disease\n* neutropenia\n* radiation\n* active intestinal disease","ALL","65 Years","85 Years",{"count":68,"type":69},40,"ESTIMATED","INTERVENTIONAL",[72],"EARLY_PHASE1","The main objective is to investigate whether administration of probiotics to patients with mild Alzheimer's Disease (AD) reduces neuroinflammation, improves cognitive function and modifies neurophysiological measures, compared to a patient group that receives placebo (no active probiotics).",[75,76],"Neurodegenerative Diseases","Cognition Disorders in Old Age",[78,79,80,81,82,83],"probiotics","Electroencephalogram (EEG)","cognitive function","Alzheimer's Disease","neuropsychological testing","Electrocardiogram (EKG)","2024-12-03",{"date":86,"type":87},"2024-12-05","ACTUAL",{"date":89,"type":87},"2022-12-19",{"date":91,"type":69},"2025-12-01",{"name":5,"class":6},1]